7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.
We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Saika M et al. | 17beta-estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-alpha. | 2001 | Endocrinology | pmid:11356664 |
Mackie PS et al. | Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line. | 2001 | Br. J. Cancer | pmid:11286476 |
Hofbauer LC et al. | Osteoprotegerin, RANK, and RANK ligand: the good, the bad, and the ugly in rheumatoid arthritis. | 2001 | J. Rheumatol. | pmid:11327234 |
Hofbauer LC and Heufelder AE | The role of osteoprotegerin and receptor activator of nuclear factor kappaB ligand in the pathogenesis and treatment of rheumatoid arthritis. | 2001 | Arthritis Rheum. | pmid:11229454 |
Leach RJ et al. | The genetics of Paget's disease of the bone. | 2001 | J. Clin. Endocrinol. Metab. | pmid:11231972 |
Luger NM et al. | Osteoprotegerin diminishes advanced bone cancer pain. | 2001 | Cancer Res. | pmid:11358823 |
Goltzman D | Osteolysis and cancer. | 2001 | J. Clin. Invest. | pmid:11375409 |
Zhang J et al. | Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. | 2001 | J. Clin. Invest. | pmid:11375413 |
Kostenuik PJ and Shalhoub V | Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption. | 2001 | Curr. Pharm. Des. | pmid:11375772 |
Thirunavukkarasu K et al. | Stimulation of osteoprotegerin (OPG) gene expression by transforming growth factor-beta (TGF-beta). Mapping of the OPG promoter region that mediates TGF-beta effects. | 2001 | J. Biol. Chem. | pmid:11451955 |
Sasaki N et al. | Glucocorticoid decreases circulating osteoprotegerin (OPG): possible mechanism for glucocorticoid induced osteoporosis. | 2001 | Nephrol. Dial. Transplant. | pmid:11239019 |
Takeuchi T et al. | Adrenergic stimulation of osteoclastogenesis mediated by expression of osteoclast differentiation factor in MC3T3-E1 osteoblast-like cells. | 2001 | Biochem. Pharmacol. | pmid:11239501 |
Mori K et al. | Cross-talk between RANKL and FRP-1/CD98 Systems: RANKL-mediated osteoclastogenesis is suppressed by an inhibitory anti-CD98 heavy chain mAb and CD98-mediated osteoclastogenesis is suppressed by osteoclastogenesis inhibitory factor. | 2001 | Cell. Immunol. | pmid:11243701 |
Hofbauer LC et al. | Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. | 2001 | Biochem. Biophys. Res. Commun. | pmid:11162519 |
Brändström H et al. | Regulation of osteoprotegerin secretion from primary cultures of human bone marrow stromal cells. | 2001 | Biochem. Biophys. Res. Commun. | pmid:11162596 |
Wuyts W et al. | Evaluation of the role of RANK and OPG genes in Paget's disease of bone. | 2001 | Bone | pmid:11165949 |
Michigami T et al. | Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma. | 2001 | Cancer Res. | pmid:11245477 |
Wada N et al. | Periodontal ligament cells secrete the factor that inhibits osteoclastic differentiation and function: the factor is osteoprotegerin/osteoclastogenesis inhibitory factor. | 2001 | J. Periodont. Res. | pmid:11246705 |
Jung K et al. | Osteoprotegerin in serum as a novel marker of bone metastatic spread in prostate cancer. | 2001 | Clin. Chem. | pmid:11673385 |
Lean JM et al. | FLT3 ligand can substitute for macrophage colony-stimulating factor in support of osteoclast differentiation and function. | 2001 | Blood | pmid:11675341 |
Fiumara P et al. | Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines. | 2001 | Blood | pmid:11675352 |
Satoh K et al. | Tumor necrosis factor-related apoptosis-inducing ligand and its receptor expression and the pathway of apoptosis in human pancreatic cancer. | 2001 | Pancreas | pmid:11590320 |
Yano K et al. | Immunological study on circulating murine osteoprotegerin/osteoclastogenesis inhibitory factor (OPG/OCIF): possible role of OPG/OCIF in the prevention of osteoporosis in pregnancy. | 2001 | Biochem. Biophys. Res. Commun. | pmid:11594776 |
Brown JM et al. | Serum osteoprotegerin levels are increased in patients with advanced prostate cancer. | 2001 | Clin. Cancer Res. | pmid:11595685 |
Miyamoto T et al. | Bifurcation of osteoclasts and dendritic cells from common progenitors. | 2001 | Blood | pmid:11588053 |
Pearse RN et al. | Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. | 2001 | Proc. Natl. Acad. Sci. U.S.A. | pmid:11562486 |
Kostenuik PJ et al. | OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats. | 2001 | Endocrinology | pmid:11564687 |
Marco-Mingot M et al. | Lack of mutations in the RANK gene in Spanish patients with Paget disease of bone. | 2001 | Clin. Genet. | pmid:11531977 |
Raffai RL et al. | Introduction of human apolipoprotein E4 "domain interaction" into mouse apolipoprotein E. | 2001 | Proc. Natl. Acad. Sci. U.S.A. | pmid:11553788 |
Hocking LJ et al. | Genomewide search in familial Paget disease of bone shows evidence of genetic heterogeneity with candidate loci on chromosomes 2q36, 10p13, and 5q35. | 2001 | Am. J. Hum. Genet. | pmid:11555792 |
Hofbauer LC et al. | Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases. | 2001 | Cancer | pmid:11505389 |
Hofbauer LC and Heufelder AE | Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. | 2001 | J. Mol. Med. | pmid:11485016 |
Furuya D et al. | Immuno-PCR assay for homodimeric osteoprotegerin. | 2001 | Clin. Chem. | pmid:11468243 |
Seck T et al. | Serum parathyroid hormone, but not menopausal status, is associated with the expression of osteoprotegerin and RANKL mRNA in human bone samples. | 2001 | Eur. J. Endocrinol. | pmid:11454517 |
Burguera B et al. | Leptin reduces ovariectomy-induced bone loss in rats. | 2001 | Endocrinology | pmid:11459801 |
Yamagishi T et al. | Reciprocal control of expression of mRNAs for osteoclast differentiation factor and OPG in osteogenic stromal cells by genistein: evidence for the involvement of topoisomerase II in osteoclastogenesis. | 2001 | Endocrinology | pmid:11459812 |
Ma YL et al. | Catabolic effects of continuous human PTH (1--38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. | 2001 | Endocrinology | pmid:11517184 |
Bateman TA et al. | Osteoprotegerin ameliorates sciatic nerve crush induced bone loss. | 2001 | J. Orthop. Res. | pmid:11518255 |
Halladay DL et al. | Identification of signal transduction pathways and promoter sequences that mediate parathyroid hormone 1-38 inhibition of osteoprotegerin gene expression. | 2001 | J. Cell. Biochem. | pmid:11746511 |
Cao Y et al. | IKKalpha provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development. | 2001 | Cell | pmid:11747812 |
Chung H et al. | Deflazacort increases osteoclast formation in mouse bone marrow culture and the ratio of RANKL/OPG mRNA expression in marrow stromal cells. | 2001 | J. Korean Med. Sci. | pmid:11748360 |
Komuro H et al. | The osteoprotegerin/receptor activator of nuclear factor kappaB/receptor activator of nuclear factor kappaB ligand system in cartilage. | 2001 | Arthritis Rheum. | pmid:11762937 |
Lindberg MK et al. | Estrogen receptor alpha, but not estrogen receptor beta, is involved in the regulation of the OPG/RANKL (osteoprotegerin/receptor activator of NF-kappa B ligand) ratio and serum interleukin-6 in male mice. | 2001 | J. Endocrinol. | pmid:11739008 |
Brown JM et al. | Osteoprotegerin and rank ligand expression in prostate cancer. | 2001 | Urology | pmid:11306358 |
Fukagawa M et al. | [PTH and bone metabolism in chronic dialysis patients]. | 2001 | Rinsho Byori | pmid:11307321 |
Horowitz MC et al. | Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands. | 2001 | Cytokine Growth Factor Rev. | pmid:11312114 |
Lin DL et al. | Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro. | 2001 | Prostate | pmid:11351351 |
Sparks AB et al. | Mutation screening of the TNFRSF11A gene encoding receptor activator of NF kappa B (RANK) in familial and sporadic Paget's disease of bone and osteosarcoma. | 2001 | Calcif. Tissue Int. | pmid:11351498 |
Disthabanchong S and González EA | Regulation of bone cell development and function: implication for renal osteodystrophy. | 2001 | J. Investig. Med. | pmid:11352181 |
Kotake S et al. | Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. | 2001 | Arthritis Rheum. | pmid:11352231 |